Clinical trial · Interventional
Pre Procedural Biomarkers Might Predict Recurrent Atrial Fibrillation After Catheter Ablation
Pre Procedural High Serum Visfatin and Tumor Necrosis Factors "Alpha" Might Predict Recurrent Atrial Fibrillation After Catheter Ablation
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Evaluation of the predictive value of serum levels of adipocytokines and primary phase reactant for recurrent atrial fibrillation (RAF) after catheter ablation in 26 patients had persistent and 91 patients had paroxysmal AF. During 12-m follow-up, 41 patients had RAF (35%). Patients had RAF were significantly older, had significantly higher BMI, lower ejection fraction and wider maximal left atrial diameter (LAD). Serum hs-CRP, IL-6, TNF-α, visfatin, and adiponectin levels were significantly higher in patients developed. Elevated serum levels of TNF-α, visfatin and adiponectin are a significant positive predictors for RAF.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Atrial Fibrillation | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Measuring Serum bio-markers | Diagnostic Test | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- ACTIVE_COMPARATOR
- label
- Recurrent Atrial fibrillation
- description
- patients developed Recurrent Atrial fibrillation catheter ablation
- interventionNames
- Diagnostic Test: Measuring Serum bio-markers
- type
- ACTIVE_COMPARATOR
- label
- NO Recurrent Atrial fibrillation
- description
- patients didn't develop Recurrent Atrial fibrillation catheter ablation
- interventionNames
- Diagnostic Test: Measuring Serum bio-markers
Primary outcomes (1)
- measure
- Recurrent Atrial Fibrillation
- timeFrame
- 12 months
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 50 Years
- Maximum age
- 70 Years
Show eligibility criteria text
Inclusion Criteria: * Symptomatic paroxysmal or persistent AF that was resistant to medical acceptable daily dose therapy in patients who were free of exclusion criteria and accepted to sign the written fully informed consent to undergo CA and to give pre-procedural blood samples. Exclusion Criteria: * History of the presence of longstanding persistent or permanent AF, * myocardial infarction, acute coronary syndrome (ACS), * significant heart failure (NYHA3), * dilated or hypertrophic cardiomyopathy, * left ventricular ejection fraction (LVEF)\< 35%, congenital pathologies, * significant valvular heart disease, * pulmonary embolism, * venous thrombosis, * intracardiac thrombus or inability to take warfarin or other oral anticoagulants, * hepatic or renal insufficiency, * acute inflammatory states (sepsis, chronic obstructive pulmonary disease in acute phase), * cancer, * autoimmune pathologies.
References
Publications (0)
Data not yet available